A recent study has identified potential targets andmolecular mechanisms of BDMC in IBD, indicating that BDMC may reducethe release of proinflammatory cytokines by potentially targetingnonreceptor tyrosine kinase (SRC), epidermal growth factor receptor(EGFR), AKT threonine-protein kinase (AKT1), and phosphoinositide-3-kinaseregulatory subunit 1 (PIK3R1), with notable effects on the PI3K/AKTand mitogen-activated protein kinase (MAPK) pathways. The gene discussed is EGFR; the disease is irritable bowel syndrome.